Q3 2017 13F Holders as of 9/30/2017
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
28M
-
Number of holders
-
64
-
Total 13F shares, excl. options
-
12M
-
Shares change
-
+1.12M
-
Total reported value, excl. options
-
$177M
-
Value change
-
+$16.4M
-
Number of buys
-
47
-
Number of sells
-
-11
-
Price
-
$14.72
Significant Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) as of Q3 2017
68 filings reported holding SYRS - Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value as of Q3 2017.
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) has 64 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 12M shares
of 28M outstanding shares and own 42.97% of the company stock.
Largest 10 shareholders include FMR LLC (3.94M shares), DEERFIELD MANAGEMENT CO (1.27M shares), WELLINGTON MANAGEMENT GROUP LLP (996K shares), Redmile Group, LLC (641K shares), BAKER BROS. ADVISORS LP (575K shares), BlackRock Inc. (570K shares), VANGUARD GROUP INC (550K shares), Aisling Capital LLC (509K shares), PRICE T ROWE ASSOCIATES INC /MD/ (309K shares), and Cormorant Asset Management, LLC (296K shares).
This table shows the top 64 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.